Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Maravai Lifesciences Holdings (MRVI) over the last 3 years, with Dec 2024 value amounting to $322.4 million.

  • Maravai Lifesciences Holdings' Cash & Equivalents fell 57.87% to $243.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.6 million, marking a year-over-year decrease of 57.87%. This contributed to the annual value of $322.4 million for FY2024, which is 43.93% down from last year.
  • Maravai Lifesciences Holdings' Cash & Equivalents amounted to $322.4 million in FY2024, which was down 43.93% from $575.0 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Cash & Equivalents ranged from a high of $632.1 million in FY2022 and a low of $322.4 million during FY2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $575.0 million (2023), whereas its average is $509.8 million.
  • Data for Maravai Lifesciences Holdings' Cash & Equivalents shows a maximum YoY plummeted of 43.93% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Maravai Lifesciences Holdings' Cash & Equivalents stood at $632.1 million in 2022, then decreased by 9.04% to $575.0 million in 2023, then crashed by 43.93% to $322.4 million in 2024.